Teleflex (TFX) announced the publication of a new retrospective analysis of clinical data associating the use of the Titan SGS Stapler with reduced rates of post-operative gastroesophageal reflux disease, or GERD, following robotic-assisted laparoscopic sleeve gastrectomy, or LSG, compared with traditional multi-fire surgical staplers. The retrospective study comprised 257 patients who underwent robot-assisted sleeve gastrectomy using the Titan SGS Stapler or multiple fires of a traditional linear stapler between 2016 and 2023. Sleeve gastrectomy is the most common weight-loss surgery in the U.S. A 2024 review of 109 studies found “a persistent concern for worsening and de novo GERD” after sleeve gastrectomy. The Titan SGS Stapler is designed to improve the potential to resolve GERD and nausea. The publication reports that at one-year post-procedure, significantly fewer patients in the Titan SGS Stapler cohort reported having GERD vs. the multi-fire cohort and significantly fewer patients in the Titan SGS Stapler cohort developed de novo GERD vs. the multi-fire cohort. In previous retrospective studies, the Titan SGS Stapler has been associated with significantly reduced operative times, less post-op nausea and vomiting and the potential for increased operational efficiencies and significant reductions in LOS and readmissions
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFX:
- Teleflex price target lowered to $145 from $150 at RBC Capital
- Teleflex price target lowered to $137 from $146 at Wells Fargo
- Teleflex Reports Q1 2025 Results and Strategic Plans
- Teleflex’s Earnings Call: Mixed Sentiments and Strategic Moves
- Teleflex’s Mixed Outlook: Strong Revenue Performance Amid Tariff Challenges and Strategic Uncertainty